Vicore Pharma Q3 2026 Earnings Results & Report

Vicore Pharma EPS Results

• Actual EPS: -$0.04
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vicore Pharma Revenue Results

• Actual Revenue: $59.34 thousand
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vicore Pharma (NASDAQ:VCRE) is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.

Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor. The company is investigating buloxibutid as a potential treatment for idiopathic pulmonary fibrosis and other forms of progressive pulmonary fibrosis. Its development programs are designed to explore the compound’s potential to reduce disease progression and support restoration of lung function.

Vicore Pharma’s portfolio also includes research programs and supportive digital health initiatives related to respiratory disease and patient care. The company’s operations and clinical programs are primarily based in Sweden and extend to international clinical research settings as appropriate for its development activities. Vicore is listed on Nasdaq Stockholm under the ticker symbol VICO.